Highlights
- •t(8;22)/BCR-FGFR1 rearrangement is a rare genetic abnormality identified in a case of myeloid/lymphoid neoplasms with FGFR1 rearrangement.
- •Sorafenib in combination with Azacytidine could be effective in patients with sole t(8;22)/BCR-FGFR1 rearrangement as complete haematological response was observed in our case.
- •Combination of Sorafenib and Azacytidine treatment can help in management of patients with sole t(8;22)/BCR-FGFR1 rearrangement where targeted therapy or HSCT transplantation is not possible.
Abstract
The sole t(8;22)(p11.2;q11.2)/BCR- FGFR1 chromosomal abnormality formerly known as aCML is an extremely rare disease entity
with a history of rapid progression. Though patients resemble phenotypically chronic
myeloid leukemia, the treatment of patients with sole BCR-FGFR1 rearrangement are still challenging for clinicians due to rapid progressive nature
and unavailability of uniform treatment guidelines. In present case study, we describe
a case of myeloid neoplasm with sole chromosomal abnormality of t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement which is successfully managed by Sorafenib with Azacitidine. Hence
our case report suggests that combination of Sorafenib and Azacitidine treatment is
effective in sole BCR-FGFR1 rearrangement, however this combination therapy should be studied in large clinical
trials.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Cancer GeneticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia.Leuk Lymphoma. 1992 Jan 1; 7: 343-350
- The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms.Leukemia. Jul 2022; 36: 1720-1748
- Myelodysplastic/myeloproliferative neoplasms.Atlas Genet Cytogenet Oncol Haematol. 2018; 22 (398–2)
- The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French-American-British Cooperative Leukaemia Group.Br J Haematol. Aug 1994; 87: 746-754
- Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia.Leuk Lymphoma. Jun 3 2015; 56: 1911-1913
- Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.Oncol Lett. Jan 1 2016; 11: 689-692
- Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes.Blood. Dec 3 2015; 126: 2812
- ChimeraScan: a tool for identifying chimeric transcription in sequencing data.Bioinformatics. Oct 15 2011; 27: 2903-2904
- FusionCatcher–a tool for finding somatic fusion genes in paired-end RNA-sequencing data.Biorxiv. Jan 1 2014; 011650
- JAFFA: High sensitivity transcriptome-focused fusion gene detection.Genome medicine. Dec 2015; 7: 1-2
- Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation.Clinical Hematology International. Sep 2020; 2: 129
- BCR: a promiscuous fusion partner in hematopoietic disorders.Oncotarget. Apr 12 2019; 10: 2738
- Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia.Genes Chromosomes Cancer. Oct 2008; 47: 915-918
- Myeloproliferative neoplasms with t (8; 22)(p11. 2; q11. 2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.Human pathology. Jul 1 2017; 65: 147-156
- A case of a patient characterized by t (8; 22)(p11; q11) and BCR/FGFR1 fusion gene, who was successfully treated with haploidentical hematopoietic stem cell transplantation.Hematology. Jan 1 2021; 26: 691-696
- A rare case of atypical chronic myeloid leukemia associated with t(8; 22)(p11.2; q11.2)/BCR-FGFR1 rearrangement: A case report and literature review.Cancer Genet. Nov 1 2021; 258: 69-73
- Activity of single-agent decitabine in atypical chronic myeloid leukemia.Journal of Oncology Pharmacy Practice. Dec 2016; 22: 790-794
- Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.Br J Haematol. Jun 2017; 177: 759-765
- Effects on cancer cells, tumor microenvironment and whole-body homeostasis.Int J Mol Med. Jul 1 2016; 38: 3-15
- Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.Eur J Haematol. Nov 2017; 99: 442-448
- Population pharmacokinetic analysis of sorafenib in patients with solid tumours.Br J Clin Pharmacol. Aug 2011; 72: 294-305
Al-jamal HA, Jusoh SM, Hassan R, Farid M. Azacytidine Enhances Efficacy of Tyrosine Kinase Inhibitors in Aml Cells.
- Atypical chronic myeloid leukemia achieving good response with azacitidine.Indian J Cancer. Oct 1 2019; 56: 354
- Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis.J Clin Pathol. Dec 1 2017; 70: 1089
Article info
Publication history
Published online: March 17, 2023
Accepted:
March 16,
2023
Received in revised form:
January 23,
2023
Received:
May 25,
2022
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
